Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

MM_BH3_CutTag

Financiado

Parallel epigenomic and apoptotic profiling to identify targetable sensitivities...

Parallel epigenomic and apoptotic profiling to identify targetable sensitivities in Multiple Myeloma Multiple Myeloma (MM) is an incurable cancer caused by uncontrolled growth of the plasma cells. A major challenge is drug resistance, which is caused by increased reliance on the anti-apoptotic BCL-2 family proteins and altered ep... ver más

31/08/2024

ROYAL COLLEGE OF S...

216K€

Presupuesto del proyecto: 216K€

Líder del proyecto

ROYAL COLLEGE OF SURGEONS IN IRELAND No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-08-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021

I+D

Cerrada hace 3 años

0% 100%

2 Participantes

ROYAL COLLEGE OF SURGEONS IN...

215.53K€ | Lider

ALMAC DISCOVERY

N.D. | Participante

Proyectos interesantes

SC-Plasticity Applying novel single-cell multiomics to elucidate leukaemia... 2M€ Cerrado

SAF2014-52614-R EL INTERACTOMA DE LOS DOMINIOS TRANSMEMBRANA DE LAS PROTEINA... 121K€ Cerrado

Sugarcoating matters Sugarcoating matters: Deciphering the effects of aberrant re... 188K€ Cerrado

ChromTrace Tracing epigenetic evolution of triple negative breast cance... 2M€ Cerrado

PID2020-115875RB-I00 DESARROLLO DE NUEVAS ESTRATEGIAS TERAPEUTICAS QUIMICAS Y BIO... 237K€ Cerrado

PID2021-124601OB-I00 ESTUDIO Y CARACTERIZACION DE DEPENDENCIAS METABOLICAS EN LIN... 230K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 24 meses Fecha Inicio: 2022-08-02
Fecha Fin: 2024-08-31

Líder del proyecto

ROYAL COLLEGE OF SURGEONS IN IRELAND

TRL 4-5

Presupuesto del proyecto 216K€

Descripción del proyecto Multiple Myeloma (MM) is an incurable cancer caused by uncontrolled growth of the plasma cells. A major challenge is drug resistance, which is caused by increased reliance on the anti-apoptotic BCL-2 family proteins and altered epigenetic landscapes. Dependence is highly variable, with distinct dependencies on BCL-2 family members (MCL-1, BCL-2 & BCL-XL) across patient samples. It is currently not understood what causes heterogeneity of BCL2 dependence in MM, and thus exploiting this reliance for treatment has proved difficult. Epigenetic modifiers regulate apoptotic pathways and therefore represent a therapeutic avenue through which cells can be sensitized to BCL2-family inhibitor treatment. I will use the cutting-edge technology CUT&Tag to assess the epigenetic landscape of MM patient samples with diverse anti-apoptotic dependence. The key aim is to identify targetable epigenetic modifiers that can be combined with BCL2 inhibitors for more effective MM therapy. I have 3 main objectives for this proposal: 1) establish parallel CUT&Tag with BH3 profiling to understand the basal epigenetic profile of MCL-1/BCL-2/BCL-XL-dependent MM; 2) to identify inter- & intra-patient epigenetic profiles characteristic of sensitive/insensitive patient samples; 3) to assess MM sensitivity to epigenetic inhibitors, and I will apply this basic research to drug development during a 6-week secondment in Almac Discovery. This project will deliver vital information on mechanisms of drug insensitivity & therapeutic avenues to target epigenetic sensitivities in MM tumors. At this critical stage in my career, it is crucial that I further diversify my skillset and apply interdisciplinary tactics to my research questions. Winning the prestigious MSCA-PF will allow me to expand my skillset, gain inter-sectoral experience during secondment and foster key collaborations in clinical research. This is crucial to reach my ultimate career goal as an independent research expert in cancer epigenetics.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores